Sign in

Private company

Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. is an American pharmaceutical preparations company based in Los Gatos.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersLos Gatos, California1
  • Incorporated inDE2
  • Business address983 University Avenue, Bldg. B, Los Gatos, Ca 950322
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-970.3%Operating margin3
-982.6%Net margin3
101.4%Revenue growth, 20223
-$29.2MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$25.9M

Out of $3.1M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$3.1M in 2022+259% since 2017
0$1.0M$2.0M$3.0M$4.0M2017: $860.0K$860.0K20172018: $2.8M$2.8M2018+221%2019: $1.0M$1.0M2019−63%2020: $1.0M$1.0M2020−2%2021: $1.5M$1.5M2021+53%2022: $3.1M$3.1M2022+101%
Operating income45673-$30.0M in 2022+52% since 2017
-$60.0M-$40.0M-$20.0M02017: -$19.7M-$19.7M20172018: -$24.1M-$24.1M2018+22%2019: -$29.1M-$29.1M2019+21%2020: -$22.4M-$22.4M2020−23%2021: -$42.7M-$42.7M2021+91%2022: -$30.0M-$30.0M2022−30%
Net income45673-$30.4M in 2022+23% since 2017
-$60.0M-$40.0M-$20.0M02017: -$24.7M-$24.7M20172018: -$22.1M-$22.1M2018−10%2019: -$29.7M-$29.7M2019+34%2020: -$22.3M-$22.3M2020−25%2021: -$42.2M-$42.2M2021+89%2022: -$30.4M-$30.4M2022−28%
Fiscal year2016201720182019202020212022
Revenue$860.0K4$2.8M5$1.0M6$1.0M7$1.5M3$3.1M3
Research and development$17.4M4$23.0M5$24.1M6$17.0M7$36.9M3$25.9M3
Operating expenses$44.2M3$33.1M3
Operating income-$19.7M4-$24.1M5-$29.1M6-$22.4M7-$42.7M3-$30.0M3
Net income-$24.7M4-$22.1M5-$29.7M6-$22.3M7-$42.2M3-$30.4M3
Earnings per share-$164.984-$7.454-$2.447-$3.773-$1.623
Earnings per share (diluted)-$164.984-$7.454-$2.447-$3.777
Shares (weighted, basic)12.3M shares318.8M shares3
Shares (weighted, diluted)12.3M shares7

Compare Aridis Pharmaceuticals, Inc. with another company

Corporate structure

Aridis Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Aridis Pharmaceuticals, Inc.

  • Aridis Pharmaceuticals, Inc. Los Gatos, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Aridis Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.8M3 Dec 31, 2022$2.9M3 Dec 31, 2021−5.7%
Accumulated depreciation$2.0M3 Dec 31, 2022$1.6M3 Dec 31, 2021+28.9%
Property and equipment, net$730.0K3 Dec 31, 2022$1.4M3 Dec 31, 2021−46.2%
Operating-lease assets (leased space)$1.4M3 Dec 31, 2022$1.9M3 Jan 1, 2022−25.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.9M3 Dec 31, 2022$18.1M3 Dec 31, 2021−73.1%
Stakes in other companies (equity method)$07 Dec 31, 2021$06 Dec 31, 2020

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$81.0K3 Dec 31, 2022$81.0K3 Dec 31, 20210%
Accumulated amortization$64.0K3 Dec 31, 2022$59.0K3 Dec 31, 2021+8.5%
Finite-lived intangibles, net$17.0K3 Dec 31, 2022$22.0K3 Dec 31, 2021−22.7%

Leadership

Who has led Aridis Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Vu Truong2018–2024

Chair

  1. Eric Patzer2021–2023

Chief financial officer

  1. Fred Kurland2018–2023
  2. Michael Adrian Nazak2020–2021
20202025
Board members and other officers (11)

Timeline

  1. Jun 27, 20248-K Entered a material agreement; Unregistered sale of shares25
  2. Jan 16, 20248-K Shareholder vote26
  3. Dec 18, 20238-K Bylaws or fiscal year changed27
  4. Nov 3, 20238-K Results of operations28
  5. Sep 7, 20238-K Listing notice or transfer29
  6. Aug 25, 20238-K Ended a material agreement30
  7. Aug 9, 20238-K Executive or director change31
  8. Jul 20, 20238-K Debt or obligation accelerated32
  9. Jul 18, 20238-K Listing notice or transfer33
  10. Jun 23, 20238-K Change of auditor34
  11. Jun 9, 20238-K Results of operations35
  12. May 25, 20238-K Listing notice or transfer; Change of auditor36
  13. Aug 13, 2018New chief executive Vu Truong becomes CEO11

Calendar

When it reported results

  1. Nov 3, 2023Reported quarterly or annual results28
  2. Jun 9, 2023Reported quarterly or annual results35
  3. Nov 22, 2022Reported quarterly or annual results37
  4. Aug 16, 2022Reported quarterly or annual results38
  5. May 16, 2022Reported quarterly or annual results39
  6. Apr 1, 2022Reported quarterly or annual results40
  7. Nov 10, 2021Reported quarterly or annual results41

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

137 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 36 major events, 32 insider forms, 14 large holders, 2 private raises, 44 other. The latest 20:

  1. Aug 14, 2026SCHEDULE 13G/A EDGAR
  2. May 15, 2026SCHEDULE 13G/A EDGAR
  3. Feb 17, 2026SCHEDULE 13G/A EDGAR
  4. Aug 14, 2025SCHEDULE 13G/A EDGAR
  5. May 15, 2025SCHEDULE 13G/A EDGAR
  6. Feb 14, 2025SCHEDULE 13G/A EDGAR
  7. Nov 14, 2024SC 13G/A EDGAR
  8. Jun 28, 20244 EDGAR
  9. Jun 28, 20244 EDGAR
  10. Jun 28, 20244 EDGAR
  11. Jun 28, 20244 EDGAR
  12. Jun 28, 20244 EDGAR
  13. Jun 27, 20248-K EDGAR
  14. Feb 14, 2024SC 13G/A EDGAR
  15. Feb 13, 2024SC 13G/A EDGAR
  16. Jan 16, 20248-K EDGAR
  17. Dec 18, 2023DEFA14A EDGAR
  18. Dec 18, 20238-K EDGAR
  19. Dec 15, 2023DEFA14A EDGAR
  20. Nov 6, 202310-Q EDGAR

The 137 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 24, 2024Patzer EricDirectorBuy714,286$0.07$50.0KForm 4
Jun 24, 2024Truong VuCEOBuy714,286$0.07$50.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$13.6M 2020–2022
Money received by yearMoney received by year, 2020–2022: $13.6M in all. Private raises (Form D) $12.8M; PPP loans $714.5K.$0$5M$10M$15M2020 · PPP loans: $714.5K202020212022 · Private raises (Form D): $12.8M2022
Figures by year
YearPrivate raises (Form D)PPP loansTotal
2022$12.8M–$12.8M
2020–$714.5K$714.5K

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Dec 7, 2022Raised $4.8 million in a private offering of equity47 Form D: 1 investor so far Form D
  2. Oct 7, 2022Raised $8 million in a private offering of equity48 Form D: 1 investor so far Form D

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA49. Matched to this company by name and state.

  1. Apr 27, 2020$714.5K PPP loan (first draw) from Silicon Valley Bridge Bank NA49To ARIDIS PHARMACEUTICALS, INC., San Jose CA; $722.1K forgiven May 21, 2021

SEC filer profile

How Aridis Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAridis Pharmaceuticals, Inc.1
  • CIK0001614067
  • Employer ID (EIN)32-00745001
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address983 University Avenue, Bldg. B, Los Gatos, CA 950321
  • Phone(408) 385-17421
  • Shares outstanding44,574,021 as of Sep 30, 202310
  • Public float$12.2M as of Jun 30, 20223
  • On EDGAR sinceJul 17, 20141
  • Filings314 in all: 8-K (88), 4 (50), CORRESP (18), 10-Q (17), 3 (14), UPLOAD (14), 424B5 (11), S-1/A (10)1
    All 37 form types

    D (7), 3/A (6), 4/A (6), EFFECT (6), SCHEDULE 13G/A (6), 10-K (5), DEF 14A (5), SC 13G (5), SC 13G/A (5), DEFA14A (4), NT 10-Q (4), S-8 (4), 10-K/A (3), 8-K/A (3), NT 10-K (3), S-1 (3), S-3 (3), 424B3 (2), DRS (2), 10-Q/A (1), 25-NSE (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), CT ORDER (1), DRS/A (1), DRSLTR (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) May 22, 2023
    Quarterly report (10-Q) Nov 6, 2023
    Proxy statement (DEF 14A) Nov 3, 2023
    Latest 8-K (8-K) Jun 27, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49